Multiple myeloma – DREAMM-7 update
Presented by Prof Claudio Cerchione (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Italy)
Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, one of the authors of the DREAMM7 study, gave a summary of the main outcomes of the study presented at ASCO24.
In the DREAMM-7 clinical trial, the combination of belantamab mafodotin with bortezomib and dexamethasone (BVd) exhibited a statistically significant and clinically meaningful PFS advantage compared to the standard-of-care regimen of daratumumab, bortezomib and dexamethasone (DVd) in patients with RRMM who had received at least one prior line of treatment. The PFS was 36.6 months in the experimental BVd arm versus 13 months in the DVd control group. At ASCO, subgroup analyses were presented, confirming a consistent benefit across all prespecified subgroups, including patients refractory to lenalidomide and patients with one or more high-risk cytogenetic abnormalities. These findings, demonstrating significant efficacy in subgroups with high unmet medical needs, support the potential of BVd as a new standard of care in this clinical setting.
References:
Matteos MV, ASCO24, #7503
With the educational support of:
